CD19 and acute lymphoblastic leukemia: In addition, treatments with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cells in patients with relapsed acute lymphoblastic leukemia (ALL) or refractory B-cell lymphomas showed limited success12,13.